Jonathan Gutman, MD

Research Interests

Publications

• Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein IR, Riddell SR, and Delaney C. Single unit dominance following double unit umbilical cord blood transplantation coincides with a specific CD8+ T cell response against the non-engrafted unit. Blood, 2010;115:757-65
• Gutman JA, Leisenring W, Appelbaum FR, Woolfrey AE, Delaney C. Low relapse without excessive transplant related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biology of Blood and Marrow Transplant 2009;15:1122-9.
• Delaney C, Gutman JA, and Appelbaum FR. Cord blood transplantation for hematologic malignancies: conditioning regimens, double cord transplant, and infectious complications. British Journal of Haematology, 2009;147:207-16.
• Brunstein CG, Gutman JA, Defor TE, Gooley T, Verneris MR, Woolfrey A, Weisdorf DJ, Appelbaum FR, Wagner JE, Delaney C. Reduced relapse and similar progression-free survival after double umbilical cord blood transplantation (DUCBT): comparison of outcomes between sibling, unrelated adult and unrelated DUCB hematopoietic stem cell (HSC) donors. Oral presentation. ASH 2009.
• Miller CN, Miller SN, Flannery S, Stockinger S, Gutman JA, Quinones R, Freed BM. Relative efficiency of cord blood RBC depletion by SEPAX elutriation and manual reduction. Poster presentation, ASBMT 2010.
• Brunstein CG, Gutman JA, Defor TE, Gooley T, Verneris MR, Woolfrey A, Weisdorf DJ, Appelbaum FR, Wagner JE, Delaney C. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010;116;4693-9.
• Gutman JA, Riddell SR, McGoldrick S, Delaney C. Double unit cord blood transplantation: Who wins – and why do we care? Chimerism 2010;1:21-23.
• Gutman JA. Are there any pulmonary issues specifically related to cord blood transplants? In: Azoulay E (ed) Pulmonary Involvement in Patients with Hematological Malignancies. Springer- Verlag Berlin Heidelberg 2011 (in press).
• Gutman JA. Pulmonary veno-oocclusive disease. In: Azoulay E (ed) Pulmonary Involvement in Patients with Hematological Malignancies. Springer- Verlag Berlin Heidelberg 2011 (in press).
• Gutman JA, Heimfeld S, and Deeg HJ. Alternative sources of hematopoietic stem cells and their clinical applications. In: Wiernik P, Goldman J, Dutcher J, Kyle R (eds) Neoplastic Diseases of the Blood, 5th edition. Springer (submitted).
• Newell LF, Gutman JA, Milano F, Riffkin I, Lopez MJ, Ziegler D, Nemecek ER, Delaney C. Treosulfan-based Conditioning is Sufficient to Promote Engraftment in Cord Blood Transplantation. Poster presentation, International Cord Blood Symposium 2010.
• Milano F, Pergam SA, Xie H, Gutman JA, Riffkin I, Newell LF, Boeckh MJ, Delaney C. Pre-Transplant Ganciclovir and High-Dose Acyclovir Decrease Incidence of CMV Reactivation in Seropositive UCBT Recipients. Poster presentation, International Cord Blood Symposium 2010.
• Milano F, Pergam SA, Xie H, Gutman JA, Riffkin I, Chow V, Newell LF, Boeckh MJ, Delaney C. Pre-Transplant Ganciclovir and High-Dose Valacyclovir Prophylaxis Decrease Incidence of CMV Reactivation in High-risk Seropositive UCBT Recipients. Oral presentation. ASH 2010.
• Milano F, Riffkin I, Newell LF, Gutman JA, Chien JW, Delaney C. Stable Pulmonary Function Observed Over Time in Recipients of Myeloablative Double Cord Blood Transplant: a Single Center Experience. Poster presentation. ASBMT 2011.
• Newell LF, Milano F, Gutman JA, Riffkin I, Lopez MJ, Ziegler D, Nemecek ER, Delaney C. Treosulfan-based Conditioning is Sufficient to Promote Engraftment in Cord Blood Transplantation. Poster presentation. ASBMT 2011.
• A novel CEBPA germline variant in a case of acute myeloid leukemia. Leukemia and Lymphoma (Jan 2012 epub ahead of print).
• Milano F, Chien JW, Riffkin I, Gutman JA, Newell L, Pergam SA, Delaney C. Stable long-term pulmonary function after myeloablative double cord blood transplant. Biology of Blood and Marrow Transplant 2012;18:309-13.
• Milano F, Pergam SA, Xie H, Leisenring WM, Gutman JA, Riffkin I, Chow V, Boeckh MJ, Delaney C. Intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplant recipients. Blood 2011;118:5689-96.
• Gutman JA, Miller S, Kuenne S, Oppenheim J, Stark C, Zarlengo G, Quinones R, Freed BM. Cord blood collection after cesarean section improves banking efficiency. Transfusion 2011;51:2050-1.
• Petz L, Tonai R, Redai I, Li S, Li H, Bryson Y, Regan D, Spellman S, Gragert L, Boo M, Gutman J, Armitage S, Shpall E, Lin A, Rosenthal J, Zaia J, Rossi J, Kurtzberg J, Forman S, Chow R. Cord Blood Transplantation for Long Term Management or Possible Cure of HIV Infection. Oral presentation ASBMT 2012.
• Milano F, Deeg JH, Gutman JA, Eneida, NR, Delaney, C. Treosulfan-Based Conditioning for Umbilical Cord Blood Recipients Is Safe and Effective: Results from an Ongoing Phase-II Study. Poster presentation. ASBMT 2012.
• Ostronoff F, Milano F, Gooley T, Gutman J, McSweeney PA, Petersen F, Sandmaier BM, Storb R, Delaney C. Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen. Poster presentation. ASH 2011.
• Newell LF, Gutman JA, Delaney C. Hematopoietic stem cell transplantation alternate donors – a role for umbilical cord blood transplantation for hematologic malignancies. In: Estey E and Appelbaum FR (eds) Leukemia and Related Disorders: Integrated Treatment Approaches. Humana Press 2012. 219-251.
• Gutman JA, Smith K, and Pagel J. Chronic lymphocytic leukemia. In: Estey E and Appelbaum FR (eds) Leukemia and Related Disorders: Integrated Treatment Approaches. Humana Press 2012. 67-97.
• Coffey DG, Pollyea DA, Myint H, Smith C, Gutman JA. Adjusting DLCO for hemoglobin and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. Bone Marrow Transplantation (in press).
• Ostronoff F, Milano F, Gooley T, Gutman JA, McSweeney P, Petersen F, Sandmaier BM, Storb R, Delaney C. Umbilical cord blood transplantation in patients with hematological malignancies using a non-ATG containing reduced intensity preparative regimen. Bone Marrow Transplantation (e pub ahead of print).
• Petz L, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Bravo A, Tonai R, Santos S, Spellman S, Gragert L, Boo M, Rossi J, Li S, Li H, Senitzer D, Rosenthal J, Zaia J, Forman S, Chow R. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biology of Blood and Marrow Transplant 2013;19:393-7.
• Gyurkocza B, Gutman J, Nemecek ER, Sickle E, Bar M, Baumgart J, Storer B, Appelbaum F, Deeg HJ. Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-dose (2 Gy) Total Body Irradiation followed by Hematopoietic Cell Transplantation from Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Oral presentation ASH 2012.
• Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of Ph+ALL and CML. Drugs of Today (in press).
• Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ. Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2014 Jan 16. [Epub ahead of print] PubMed PMID: 24440648
• Narayanan V, Gutman JA, Pollyea DA, Jimeno A. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. Drugs Today (Barc). 2013 Jul;49(7):447-56. PubMed PMID: 23914353
• Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Drugs Today (Barc). 2013 Apr;49(4):261-9. PubMed PMID: 23616953
• Coffey DG, Pollyea DA, Myint H, Smith C, Gutman JA. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. Bone Marrow Transplant. 2013 Sep;48(9):1253-6. PubMed PMID: 23503530
• Pollyea DA, Gutman JA. Stopping higher-risk myelodysplastic syndrome in its tracks. Curr Hematol Malig Rep. 2014 Dec;9(4):421-31. PubMed PMID: 25208927
• Ostronoff F, Milano F, Gooley T, Gutman JA, McSweeney P, Petersen FB, Sandmaier BM, Storb R, Delaney C. Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin. Bone Marrow Transplant. 2013 Jun;48(6):782-6. PubMed PMID: 23241738
• Bird GA, Polsky A, Estes P, Hanlon T, Hamilton H, Morton JJ, Gutman J, Jimeno A, Turner BC, Refaeli Y. Expansion of human and murine hematopoietic stem and progenitor cells ex vivo without genetic modification using MYC and Bcl-2 fusion proteins. PLoS One. 2014;9(8):e105525. PubMed PMID: 25170611
• Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Tonai R, Santos S, Bravo A, Spellman S, Gragert L, Rossi J, Li S, Li H, Senitzer D, Zaia J, Rosenthal J, Forman S, Chow R. Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant. 2013 Mar;19(3):393-7. PubMed PMID: 23089564
• Pollyea DA, Gutman JA, Gore L, Smith CA, Jordan CT. Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica. 2014 Aug;99(8):1277-84. PubMed PMID: 25082785
• Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. PubMed PMID: 24440648
• Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group. (Gutman J 10/26) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227-36.
• Gutman JA, Myint H, Lee CK, Smith C, Nguyen V, Pollyea DA. Graft Versus Host Disease and Immunosuppression Burden Is Significantly Lower Following Adult Cord Blood Transplantation Versus Matched Unrelated Donor Transplantation. Oral presentation ASBMT 2014.
• Gavin K, Kohrt W, Gutman J, Majka S, and Klemm D. De Novo Generation of Adipocytes from Bone Marrow in Human Adipose Tissue. Keystone Obesity Conference 2014.
• Gutman JA, Schmidt C, Freed B, Palmer B. PD-1 expression on total and CMV-specific T cells early transplant is associated with donor source, T cell maturation profile and effectiveness of CMV control. ASH 2013.
• Babilonia KM, Golightly LK, Gutman JA, Hassell KL, Kaiser JN, Kiser TH, Klem PM, Trujillo TC. Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization. Clin Appl Thromb Hemost. 2014 Nov;20(8):799-806. PubMed PMID: 25022565
• Gavin K, Kohrt W, Gutman J, Majka S, and Klemm D. De Novo Generation of Adipocytes from Bone Marrow in Human Adipose Tissue. Keystone Obesity Conference 2014. Oral
• Gutman JA, Myint H, Lee CK, Smith C, Nguyen V, Pollyea DA. Graft Versus Host Disease and Immunosuppression Burden Is Significantly Lower Following Adult Cord Blood Transplantation Versus Matched Unrelated Donor Transplantation. ASBMT 2014. Oral
• Gutman JA, Myint H, Lee CK, Smith C, Nguyen V, Milano F, Salit R, Delaney C, Pollyea DA. Graft Versus Host Disease and Immunosuppression Burden Is Significantly Lower Following Adult Cord Blood Transplantation Versus Matched Unrelated Donor Transplantation. International Cord Blood Conference 2014. Oral
• Pollyea DA, Coutre SE, Gore L, Adler N, Harris P, Phelps M, Johnson AJ, Ling Y, Li H, Gutman JA, John C. Byrd JC. A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ASH 2014. Poster
• Pollyea DA, Smith C, Nguyen V, Fullerton A, Schatz D, Bedrick E, Gutman JA. Sequential azacitidine and high-dose lenalidomide for relapsed and refractory high-risk MDS and AML: Interim analysis of a phase 2 study. ASH 2014. Poster
• Delaney C, Milano F, Nicoud I, Heimfeld S, Karanes C, Gutman J, Wagner J, Appelbaum F, Bernstein I. Overcoming delayed neutrophil recovery in cord blood transplantation by infusion of cord blood progenitors ex vivo expanded in the presence of Notch ligand: Results from a multi-center phase I trial. ASH 2013.
• Salit RB, Milano F, Gutman JA, Maris MB, Chauncey T, Petersen F, and Delaney C. Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen. ASH 2013.
• Hohensee SE, Aubrey MT, Gutman J, Freed BM. Persistence of Donor-Derived HLA Antibodies In A Stem Cell Transplant Recipient. AABB 2013.
• White JT, Kurche JS, Gutman JA,* Kedl RM.* Varying frequencies of T cells exhibiting CMV peptide-specific reactivity to allo-MHC are present in cord blood transplant units. AAI 2013.
• Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational design of a parthenolide-based drug regimen that selectively eradicates acute myelogenous leukemia stem cells. J Biol Chem. 2016 Nov 25;291(48):25280. PubMed PMID: 27888238
• 32. Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of Neutrophilia Associated with Plasma Cell Neoplasms: Report of a SETBP1 Mutation and Analysis of a Single Institution Series. Leuk Lymphoma. 2015 21:1-22. [Epub ahead of print]
• Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem. 2016 Oct 14;291(42):21984-22000. PubMed PMID: 27573247
• Schade H, Sen S, Neff CP, Freed BM, Gao D, Gutman JA, Palmer BE. Programmed Death 1 Expression on CD4( ) T Cells Predicts Mortality after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Dec;22(12):2172-2179. PubMed PMID: 27519280
• Gutman JA, Ross K, Smith C, Myint H, Lee CK, Salit R, Milano F, Delaney C, Gao D, Pollyea DA. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transplant. 2016 Dec;51(12):1588-1593. PubMed PMID: 27400068
• Gavin KM, Gutman JA, Kohrt WM, Wei Q, Shea KL, Miller HL, Sullivan TM, Erickson PF, Helm KM, Acosta AS, Childs CR, Musselwhite E, Varella-Garcia M, Kelly K, Majka SM, Klemm DJ. De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue. FASEB J. 2016 Mar;30(3):1096-108. PubMed PMID: 26581599
• 33. Gavin KM, Gutman JA, Kohrt WM, Wei Q, Shea KL, Miller HL,Sullivan TM, Erickson PF, Helm KM, Acosta AS, Child CR, Musselwhite5 E, Varella-Garcia5 M, Kelly K, Majka SM and Klemm DJ. De Novo Generation of Adipocytes from Circulating Progenitor cells in Human and Mouse Adipose Tissue. FASEB Journal. [Epub ahead of print]
• Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, Jordan CT, Lee CK, Swisshelm K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, Pollyea DA. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leuk Lymphoma. 2016;57(4):927-34. PubMed PMID: 26389776
• 41. Sorror ML, Sandmaier BM, Storer B, Chauncey T, Shizuru J, Franke GN, Pulsipher M, Maris M, Bruno B, Andersen NS, Hari P, Langston A, Agura E, Sahebi F, Maziarz FR, Petersen F, Bethge W, Gutman J, Olesen G, Yeager A, Hubel K, Hogan W, Mielcarek M, Georges G, Maloney DG, Storb R. ,Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter? ASBMT 2016. Oral
• 7. Petz LD, Burnett J, Li H, Li S, Tonai R, Baklinskaya M, Shpall E, Armitage S, Kurtzberg J, Regan D, Clark P, Querol S, Gutman J, Spellma S, Gragert L, Rossi J. Progress toward Curing HIV with Hematopoietic Cell Transplantation. Stem Cells and Cloning: Advances and Applications 2015;8:109-116
• 40. Sandmaier BM, Maloney DG, Storer B, Olesen G, Maris M, Gutman J, Petersen SL, Langston A, Chauncey T, Bethge WA, Pulsipher MA, Kornblit B, Woolfrey A, Mielcarek M, Martin P, Flowers ME, Storb RF. Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial. ASH 2016. Oral
• 39. Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova, V, Stephens D, Nakamura R, Gutman J, Devine SM. Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. ASH 2016. Oral
• 36. Gutman JA, Denoncourt E, Schatz D, Tailor S, Smith C, Pollyea DA. A Phase 2 Study of the Hedgehog Pathway Smoothened Inhibitor PF-04449913 to Reduce Relapse in High Risk Acute Leukemia and MDS Patients Following Allogeneic Transplantation. ASBMT 2015. Poster
• 37. IHC Analysis and Prognostic Factors in Post Transplant Lymphoproliferative Disorders after Solid Organ Transplantation: A Single Center Experience. Nooruddin Z, Robinson W, Pollyea D, Gutman JA, Smith C, Pan Z, Jordan CT, Rabinovitch R, Schowinsky J, Lu X, Ney D, Kamdar M. ASH Blood 2015 126:1443. Poster
• Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, Purev E, Gutman JA, Robinson W, Pollyea DA. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematoligica. 2017 May;102(5):e207-e209.
• 40. Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biol Blood Marrow Transplant. 2018 Aug;24(8):1671-1677
• 41. Daniel A. Pollyea, Brett M. Stevens, Courtney L. Jones, Amanda Winters, Shanshan Pei, Mohammad Minhajuddin, Angelo D’Alessandro, Rachel Culp-Hill,Kent A. Riemondy, Austin E. Gillen, Jay R. Hesselberth, Diana Abbott5, Derek Schatz, Jonathan A. Gutman, Enkhtsetseg Purev, Clayton Smith, Craig T. Jordan. Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Acute Myeloid Leukemia Patients. Nature Medicine. 2018
• 46. Amanda C. Winters, Madeline Goosman, Brett Stevens, Enkhtsetseg Purev, Clayton Smith, Daniel A. Pollyea, Craig T. Jordan*, Jonathan Gutman* (*co-senior authors) Tracking of AML-Associated Mutations via Droplet Digital PCR is Predictive of Outcomes Post-Transplant. ASH 2018. Poster
• 47. Prashant Sharma, Enkhtsetseg Purev, Bradley M. Haverkos, Daniel A Pollyea, Clayton Smith, Manali Kamdar, Daniel W Sherbenou, Tomer M Mark, Peter A Forsberg and Jonathan Gutman. Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation. ASH 2018. Poster
• 48. Prashant Sharma, MD, Jennifer MacDonald, Jeff Kaiser, Jennifer Tobin, Matthew Miller, Maheen Abidi, Esther Benamu, Enkhtsetseg Purev, Bradley M. Haverkos and Jonathan A Gutman. Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients. ASH 2018. Poster
• 49. Pollyea DA, Jones CL, Stevens B, Pei S, D'alessandro A, Hill R, Abbott D, Hammes A, Dugan J, Gutman J, Purev E, Smith C, Jordan C. Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1. ASH 2018. Oral.
• Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 May 3. pii: blood-2017-01-761346. doi: 10.1182/blood-2017-01-761346.
• Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. N Engl J Med. 2017 Jul 6;377(1):89-91.
• Ross, K and Gutman JA. Cord blood conditioning regimens. In: Horwitz, Chao Cord Blood Transplantation. Springer 2017.
• Moyer, G; Gutman, J; DiPaola, J; Buckner, T. Incidence and characteristics of venous thromboemboli among patients undergoing allogeneic stem cell transplantation with umbilical cord blood: A preliminary analysis. HTRS 2017. Oral
• Brett Stevens, Amanda Winters, Jonathan A. Gutman, Aaron Fullerton, Gregory Hemenway, Derek Schatz, Nicholas Miltgen, Qi Wei, Taher Abbasi, Shireen Vali, Neeraj K Singh, Leylah Drusbosky, Christopher R. Cogle, Andrew Hammes, Diana Abbott, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea. Sequential Azacitidine and Lenalidomide for Patients with Relapsed and Refractory Acute Myeloid Leukemia: Clinical Results and Predictive Modeling Using Computational Analysis. Leukemia Research. 2019 Jun;81:43-49.
• Brenda M Sandmaier, MD; Brian Kornblit; Barry E Storer; Gitte Olesen; Michael B Maris; Amelia A Langston; Jonathan A Gutman;Søren L Petersen; Thomas R Chauncey; Woflgang A Bethge; Michael A Pulsipher; Ann E Woolfrey; Marco Mielcarek; Paul J Martin; Frederick R Appelbaum; Mary E Flowers; David G Maloney; Rainer Storb. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Hematology. 2019. Aug;6(8):e409-e418.
• Mark L. Laudenslager, Teresa L. Simoneau, Susan K. Mikulich-Gilbertson, Crystal Natvig, Benjamin W. Brewer, Timothy S. Sannes, Kristin Kilbourn, Jon Gutman, Peter McSweeney. A Randomized Control Trial of Stress Management for Caregivers of Stem Cell Transplant Patients: Effect on Patient Quality of Life and Caregiver Distress. Psycho-Oncology. 2019. Aug;28(8):1614-1623.
• Brett M. Stevens, Wei Zhang, Daniel Pollyea, Amanda Winters, Jonathan Gutman, Clayton Smith, Elizabeth Budde, Stephen J. Forman, Craig T. Jordan, and Enkhtsetseg Purev. CD123 CAR T cell Therapy for the Eradication of Myelodysplastic Syndrome Stem Cells. Experimental Hematology. 2019. Jun;74:52-63.
• Sharma P, Pollyea D, Smith C, Purev E, Kamdar M, Haverkos B, Sherbenou D, Gutman, J. Outcomes of Thiotepa Based Reduced Intensity Conditioning Versus Standard Reduced Intensity Conditioning in Adult Patients Undergoing Double Unit Cord Blood Hematopoietic Stem Cell Transplant. EHA. Haematologica 2107; 102(s2)
• Taylor Morrisette, Amanda Van Matre, Matthew A. Miller, Scott W. Mueller, Valida Bajrovic, Jeffrey N. Kaiser, Gerard R. Barber, Douglas N. Fish, Jonathan A. Gutman. Oral Vancomycin Prophylaxis as Secondary Prevention for Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplant and Hematologic Malignancy Population. Biol Blood Marrow Transplant. 2019. Oct;25(10):2091-2097.
• Amanda C. Winters, Jonathan A. Gutman, Enkhtsetseg Purev, Molly Nakic, Jennifer Tobin, Stephanie Chase, Jeff Kaiser, Lindsey Lyle, Chelsey Boggs, Keri Halsema, Jeffrey T. Schowinsky, Julie Rosser, Mark Ewalt, Bradford Siegele, Vishal Rana, Steven Schuster, Diana Abbott, Brett Stevens, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea. Real-World Experience of Venetoclax with Azacitidine for Untreated Patients with Acute Myeloid Leukemia. Blood Advances 2019. Oct 22;3(20):2911-2919.
• Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. (J Gutman collaborator) Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019 Jul 9;322(2):123-133.
• Prashant Sharma, Neel Gakhar, Jennifer MacDonald, Maheen Abidi, Esther Benamu, Valida Bajrovic, Enkhtsetseg Purev, Bradley M. Haverkos, Jennifer Tobin, Jeff Kaiser, Stephanie Chase, Matthew Miller, Adriana Weinberg, and Jonathan A Gutman. Letermovir prophylaxis through day 100 post-transplant is safe and effective compared to alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2019.
• Gutman JA, Pollyea DA. Hypomethylating agents with venetoclax: have we discovered the holy grail? Curr Opin Hematol. 2019 Dec 27
• Jessica Lum, Enkhtsetseg Purev, Jonathan Gutman, Kelsey Melander, J. David Beckham, Maheen Z. Abidi. Successful reduced intensity stem cell transplant in a patient with myeloproliferative neoplasm/myelodysplastic overlap syndrome diagnosed with West Nile virus encephalitis. ASBMT 2019. Poster
• Taylor Morrisette, Amanda Van Matre, Matthew A. Miller, Scott W. Mueller, Valida Bajrovic, Jeffrey N. Kaiser, Gerard R. Barber, Douglas N. Fish, Jonathan A. Gutman. Oral Vancomycin Prophylaxis as Secondary Prevention for Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplant and Hematologic Malignancy Population. MAD-ID 2019.
• Shanshan Pei, Daniel A Pollyea, Annika Gustafson, Mohammad Minhajuddin, Brett M. Stevens, Haobin Ye, Anagha Inguva, Maria L Amaya, Anna Krug, Courtney L Jones, Biniam Adane, Amanda Winters, Nabilah Khan, Jessica Ponder, Jeffrey Schowinsky, Andrew Hammes, Diana Abbott, Jason R Myers, John M Ashton, Jonathan A Gutman, Enkhtsetseg Purev, Haley E. Ramsey, Michael R. Savona, Stephen W. Fesik, Clayton Smith, and Craig T Jordan. Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy. ASH 2019. Oral.
• Amanda Winters, Jonathan A Gutman, Enkhtsetseg Purev, Brett M. Stevens, Shanshan Pei, Jeffrey Schowinsky, Diana Abbott, Andrew Hammes, Molly Nakic, Lindsey Lyle, Keri Halsema, Dwight Macero, Alex Hirose, Chelsey Boggs, Angie Falco, Natalie Monson, Shirstine Rahkola, Sarah Wright, Tyler D'Ovidio, Clayton Smith, Craig T Jordan, and Daniel A Pollyea. Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy. ASH 2019. Poster.
• Andrew Kent, Sumithira Vasu, Derek Schatz, Natalie Monson, Steven Devine, Clayton Smith, Jonathan A Gutman* and Daniel A Pollyea* (*co-senior authors). A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse ASH 2019. Poster.
• 44. Brett M. Stevens, Amanda Winters, Jonathan A Gutman, Aaron Fullerton, Gregory Hemenway, Nicholas Miltgen, Qi Wei, Taher Abbasi, Shireen Vali, Neeraj Kumar Singh, Leylah M. Drusbosky, Chris R. Cogle, Andrew Hammes, Craig T. Jordan, and Daniel A. Pollyea. Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics. ASH 2017. Poster
• Jonathan A Gutman, Prashant Sharma, Enkhtsetseg Purev, Clayton Smith, Amanda Winters, Andrew Hammes, Michael R. Loken, and Daniel A Pollyea. Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy. ASH 2019. Poster.
• Filippo Milano, Andrew R Rezvani, Joanne Kurtzberg, Chatchada Karanes, Jonathan A Gutman, Christine Duncan, Alla Keyzner, Rabi Hanna, Tonya Kimberly Marmon, Ann Dahlberg, and Colleen Delaney. No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial. ASH 2019. Oral.
• 45. Daniel A. Pollyea, Brett M. Stevens, Amanda Winters, Mohd Minhajuddin, Jonathan A Gutman, Enkhtsetseg Purev, Clayton Smith, Diana Abbott and Craig T. Jordan. Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies. ASH 2017. Oral
• 51. Prashant Sharma, Neel Gakhar, Jennifer MacDonald, Maheen Abidi, Esther Benamu, Valida Bajrovic, Enkhtsetseg Purev, Bradley M. Haverkos, Jennifer Tobin, Jeff Kaiser, Stephanie Chase, Matthew Miller, Adriana Weinberg, and Jonathan A Gutman. Letermovir prophylaxis through day 100 post-transplant is safe and effective compared to alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2020 Apr;55(4):780-786.
• 52. Gutman JA, Pollyea DA. Hypomethylating agents with venetoclax: have we discovered the holy grail? Curr Opin Hematol. 2020 Mar;27(2):76-80.
• 53. Shanshan Pei, Daniel A. Pollyea, Annika Gustafson, Brett M. Stevens, Mohammad Minhajuddin, Rui Fu, Kent A. Riemondy, Austin E. Gillen, Ryan M. Sheridan, Jihye Kim, James Costello, Maria L. Amaya, Anagha Inguva, Amanda Winters, Haobin Ye, Anna Krug, Courtney L. Jones, Biniam Adane, Nabilah Khan, Jessica Ponder, Jeffrey Schowinsky, Diana Abbott, Andrew Hammes , Jason R. Myers, John M. Ashton, Travis Nemkov, Angelo D'Alessandro, Jonathan A. Gutman, Stephen W. Fesik, Haley E. Ramsey, Michael R. Savona , Clayton A. Smith, Craig T Jordan. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients. Cancer Discovery. 2020 Apr;10(4):536-551.
• 54. Prashant Sharma, Enkhtsetseg Purev, Bradley Haverkos, Daniel A. Pollyea, Evan Cherry, Manali Kamdar, Tomer Mark, Peter Forsberg, Daniel Sherbenou, Andrew Hammes, Rachel Rabinovitch, Clayton A. Smith, Jonathan A. Gutman. Adult cord blood transplant results in comparable overall survival and improved GRFS versus matched related transplant. Blood Advances. 2020 May 26;4(10):2227-2235.
• 55. Jason P. Cooper, Barry E. Storer, Noa Granot, Boglarka Gyurkocza, Mohamed L. Sorror, Thomas R. Chauncey, Judith Shizuru, Georg-Nikolaus Franke, Michael B. Maris, Michael Boyer, Benedetto Bruno, Firoozeh Sahebi, Amelia A. Langston, Parameswaran Hari, Edward D. Agura, Søren Lykke Petersen, Richard T. Maziarz, Wolfgang Bethge, Julie Asch, Jonathan A. Gutman, Gitte Olesen, Andrew M. Yeager, Kai Hübel, William J. Hogan, David G. Maloney, Marco Mielcarek, Paul J. Martin, Mary E. D. Flowers, George E. Georges, Ann E. Woolfrey, H. Joachim Deeg, Bart L. Scott, George B. McDonald, Rainer Storb, and Brenda M. Sandmaier. Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haemalogica. 2020 Jun 4:haematol.2020.248187. Online ahead of print.
• 56. Andrew Kent, Sumithira Vasu, Derek Schatz, Natalie Monson, Steven Devine, Clayton Smith, Jonathan A. Gutman*, Daniel A. Pollyea* (shared senior authorship). Glasdegib as Maintenance Therapy for AML and MDS Patients at High Risk for Post-Allogeneic Stem Cell Transplant Relapse. Blood Advances. 2020 Jul 14;4(13):3102-3108.
• 57. Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 May 1;18(5):599-634.
• 57. Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 May 1;18(5):599-634.
• 58. Filippo Milano, Jonathan A Gutman, H. Joachim Deeg, Eneida R Nemecek, Joachim Baumgart, Laurel Thur, Ann Dahlberg, Rachel B Salit, Corinne Summers, Frederick R Appelbaum, Colleen Delaney. Treosulfan-based Conditioning is Feasibel and Effective for Cord Blood Recipients: A Phase II Multi-center Study. Blood Advances. 2020 Jul 28;4(14):3302-3310.
• 59. Matthew A Miller, PharmD, Kyle C Molina, PharmD, Jonathan A Gutman, MD, Sias Scherger, MD, Jessica M Lum, MD, Sherif B Mossad, MD, Mary Burgess, MD, Matthew P Cheng, MD, Sally T Chuang, MD, Samantha E Jacobs, MD, Dante P Melendez, MD, Dimpy P Shah, MD, Andrea Zimmer, MD, M Rizwan Sohail, MD, Sadia Syed, MD, Randall C Walker, MD, Eric M Poeschla, MD, Maheen Z Abidi, MD. Mucormycosis in Hematopoietic cell Transplant Recipients and in patients with Hematological Malignancies in the Era of New Antifungal Agents. Open Forum Infectious Diseases. 2020 12/30.
• 60. Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax?+?azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2020 Dec 30:1-9. doi: 10.1080/10428194.2020.1864358. Online ahead of print.
• 57. Mangala Iyengar, Enkhtsetseg Purev, Brad Haverkos, Clayton Smith, Daniel Pollyea, Jonathan A Gutman. Incidence of Pulmonary GVHD is Increased and Incidence of Late Infection and Pulmonary Embolism is Comparable Comparing Adult MRD Versus Cord Transplant Patients. ASBMT 2020. Poster.
• 58. Matthew A Miller, Kyle C Molina, Sias Scherger, Jessica Lum, Sherif B Mossad, Mary Burgess, Matthew P Chang, Sally Chuang, Samantha Jacobs, Dante Melendez, Dimpy P Shah, M Rizwan Sohail, Sadia Syed, Randall C Walker, Andrea Zimmer, Jonathan A Gutman, Maheen Z Abidi. Survival Among Patients with Hematologic Malignancies and Recipients of Hematopoietic Cell Transplant with Invasive Mucormycosis. ASBMT 2020. Poster.
• 59. Hannah Choe, Nirav N. Shah, Patrice Chevallier, Marie Thérèse Rubio, Mark A. Schroeder, Nancy M. Hardy, Patrick J. Stiff, Carlos Solano, Ibrahim Yakoub-Agha, Jonathan A. Gutman, Scott D. Rowley, Maria Caterina Mico, Elisabetta Terruzzi, Rafael F. Duarte, Rodica Morariu-Zamfir, Michael Arbushites, Kai Ding, and Miguel-Angel Perales. A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)–Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119). ASH 2020. Oral.
• 60. Jonathan A. Gutman, Amanda Winters, Maria L Amaya, Christine M. McMahon, Jeffrey Schowinsky, Diana Abbott, Andrew Hammes, Shanshan Pei, Brett M. Stevens, Craig T. Jordan, Clayton Smith and Daniel A. Pollyea. Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features. ASH 2020. Poster.
• 61. Daniel A. Pollyea, Amanda Winters, Craig T. Jordan, Clayton Smith, and Jonathan A. Gutman. Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy ASH 2020. Oral.
• 62. Andrew Kent, Daniel A. Pollyea, Amanda Winters, Craig T. Jordan, Clayton Smith, and Jonathan A. Gutman. Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse. ASH 2020. Poster.
• Blood type change identifies late dominance reversal of chimerism after double umbilical cord blood transplantation with review of the literature. Ho AP, Ho BE, Berg MP, Gutman JA, Draper NL.Transfusion. 2021 Feb 26.
• Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Bone Marrow Transplant. 2021 Oct 13.
• Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 Dec 28;5(24):5565-5573.
• Marc S. Schwartz, Enkhtsetseg Purev, Clayton Smith, Christine M. McMahon, Daniel A. Pollyea, Jonathan A. Gutman. Dasatinib Prednisone Is an Effective Induction Strategy Prior to Transplant for Philadelphia Chromosome Positive ALL. ASTCT 2021.
• Gutman JA. How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML. Best Pract Res Clin Haematol. 2022 Dec;35(4):101411. PubMed PMID: 36517129
• Brett M. Stevens, Amanda C. Winters, Mohammad Minhajuddin, Maria L. Amaya, Christine M. McMahon, Jonathan A. Gutman, Clayton Smith, Deng Wang, Connor Adkins, Olivia Ondracek, Craig T. Jordan and Daniel A. Pollyea. Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies. ASH 2021.
• Zhang A, Johnson T, Abbott D, Phupitakphol T, Gutman JA, Pollyea DA, Koullias Y. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine. Open Forum Infect Dis. 2022 Oct;9(10):ofac486. PubMed PMID: 36225746
• Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 3 Type Chemotherapy or Venetoclax/Azacitidine. JCO Clin Cancer Inform. 2022 Sep;6:e2200030. PubMed PMID: 36194842
• Michael T. Byrne, Tony J Kurian, Dilan A Patel, Roni Tamari, Sanghee Hong, Haitham Abdelhakim, Victoria Klein, Patricio Rojas, Raksha Madhavan, Andrew Kent, Aaron C. Logan, Catherine J. Lee, Muhammad Husnain, Benjamin M Manning, Nicholas P. Tschernia, Ajoy L. Dias, Daniel Margalski, Benjamin Goldenson, Nathalie Byrne, Heidi Chen, Kseniya Petrova-Drus, Salyka M. Sengsayadeth, Aaron M Goodman, Dianna S. Howard, William A. Wood, Saar Gill, Antonio M. Jimenez, Jonathan A. Gutman, Lohith Gowda, Leland Metheny III, Bhavana Bhatnagar, Betty K. Hamilton, Asmita Mishra, and Michael R. Savona. Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study. ASH 2021.
• Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, Gutman JA. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax   Azacitidine Versus Intensive Chemotherapy. Transplant Cell Ther. 2022 Oct;28(10):694.e1-694.e9. PubMed PMID: 35902048
• Amanda C. Winters, Grace Bosma, Diana Abbott, Mohd Minhajuddin, Craig T Jordan, Daniel A. Pollyea and Jonathan A. Gutman. Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy. ASH 2021.
• Brewer B, Sharma P, Gakhar N, Sannes TS, Joshi TK, Hunter R, Abbott D, Gutman JA. Quality of life following cord blood versus matched sibling donor transplantation: pre-transplantation psychiatric and socioeconomic factors significantly impact outcomes. Bone Marrow Transplant. 2022 Aug;57(8):1344-1346. PubMed PMID: 35618765
• Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, Abbott D, Smith CA, Gutman JA. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022 Feb;57(2):160-166. PubMed PMID: 34645926
• Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, Jordan CT, Pollyea DA. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 2023 Dec 14. [Epub ahead of print] PubMed PMID: 38105738
• Schreiber AR, Santos J, McMahon B, Buckner TW, Olson C, Alberti MO, Guimarães-Young A, Knoeckel C, Broussard L, Aubrey M, Palmer BE, Weiss E, Connors GR, Brunner S, Wisell JA, Pacheco T, Aisner DL, Gutman JA. A Case of Fetal-Induced Graft-versus-Host Disease. N Engl J Med. 2023 Aug 17;389(7):668-670. PubMed PMID: 37585636
• Abidi MZ, Molina KC, Garth K, Gutman JA, Weinberg A. Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis. Transpl Infect Dis. 2023 Oct;25(5):e14104. PubMed PMID: 37436771
• Kent A, Schwartz M, McMahon C, Amaya M, Smith CA, Tobin J, Marciano K, Rezac R, Bosma G, Pollyea DA, Gutman JA. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023 Aug;58(8):849-854. PubMed PMID: 37185614
• Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023 Oct 1;108(10):2616-2625. PubMed PMID: 37051756

Practice Locations

• University of Colorado Hospital

• University of Colorado Cancer Center

Specialty Information

• Internal Medicine, Board Certification (2005)
• Medical Oncology, Board Certification (2009)

• Cancers
• Cancers - Blood and Marrow Transplant
• Cancers - Leukemia (Adult Acute)
• Cancers - Leukemia (Adult Chronic)
• Cancers - Lymphoma
• Cancers - Myeloma